| Case series/case reports  

Post-vaccine COVID-19 in patients with multiple sclerosis or neuromyelitis optica

Recent studies suggested that anti-CD20 and fingolimod may be associated with lower anti-spike protein-based immunoglobulin-G response following COVID-19 vaccination. In this article the authors evaluated if COVID-19 occurred despite vaccination among patients with multiple sclerosis (MS) and neuromyelitis optica (NMO), using the COVISEP registry.

They report 18 cases of COVID-19 after two doses of BNT162b2-vaccination, 13 of which treated with anti-CD20 and four with fingolimod. COVID-19 severity was mild. The authors concluded that these results reinforce the recommendation for a third COVID-19 vaccine dose among anti-CD20 treated patients and stress the need for a prospective clinical and biological study on COVID-19 vaccine efficacy among MS and NMO patients.
Januel E, De Seze J, Vermersch P, Maillart E, Bourre B, Pique J, Moisset X, Bensa C, Maarouf A, Pelletier J, Vukusic S, Audoin B, Louapre C. Post-vaccine COVID-19 in patients with multiple sclerosis or neuromyelitis optica. Mult Scler. 2021 Dec 21:13524585211049737.

doi: 10.1177/13524585211049737

Back